Content for healthcare professionals only

View all Platforms Cardiology

Topics Content Type Videos Articles Journals Broadcasts Education Podcasts News Journals AER CFR ECR ICR3 JAPSC USC Faculty Events Upcoming Events Radcliffe Events All Events Resource Hubs Empagliflozin in the Treatment of Chronic Heart Failure Pulmonary Embolism Pulsed Field Ablation

Radcliffe Platforms

Radcliffe Group Cardiology Vascular CVRM Medical Education

Content for healthcare professionals only

Content Type

Events

Resource Hubs

ACC 2022: Late-breaking Science Video Collection

Published: 05 April 2022

Views:
7932
Likes:
7

Views:
7932
Likes:
7
Share:

Now Playing
Part 3 | Session 17 of 19
ACC 22: Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events
Paul M Ridker

Up Next
3m 50s

Part 3 | Session 18 ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study
Felix Mahfoud
4m

Part 3 | Session 19 2022 AHA/ACC/HFSA Guideline for HF Management: Highlights & Implementation
Michelle Kittleson

12m 6s

Part 4 | Session 1 ACC 22: 3 Trials That Will Change Your Practice with Dr Purvi Parwani
Purvi Parwani
6m 15s

Part 4 | Session 2 ACC 22: 5 Trials That Will Change Your Practice with Interventionalist, Dr Mirvat Alasnag
Mirvat Alasnag
7m 9s

Part 4 | Session 3 4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos
Erin D Michos

23m 9s

Part 1 | Session 1 ACC 22 Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen

28m 6s

Part 1 | Session 2 ACC.22 Late-breaking Science Wrap-Up Nicolas M Van Mieghem, Joost Daemen

16m 42s

Part 2 | Session 1 ACC 2022 Late-breaker Discussion: The SODIUM-HF Trial Justin Ezekowitz, Harriette Van Spall

16m 57s

Part 2 | Session 2 ACC 2022 Late-breaker Discussion: The SuperWIN Trial Harriette Van Spall, Dylan L Steen

15m 38s

Part 2 | Session 3 ACC 22 Late-breaker Discussion: The PROMPT-HF Trial Harriette Van Spall, Gregg C Fonarow, Tariq Ahmad

22m 47s

Part 2 | Session 4 ACC 22 Late-breaker Discussion: The DIAMOND Trial Harriette Van Spall, Javed Butler, Faiez Zannad

9m 38s

Part 3 | Session 1 ACC 22: Findings from the VALOR-HCM Trial Milind Y Desai

7m 19s

Part 3 | Session 2 ACC 22: MAVA-LTE Shows Improvement in NYHA Class in Patients Treated with Mavacamten Florian Rader

3m 19s

Part 3 | Session 3 ACC 22: Results From the PACIFIC AF Trial Manesh R Patel

3m 6s

Part 3 | Session 4 ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease Frederik Zimmermann

3m 54s

Part 3 | Session 5 ACC 22: Results from the TRANSLATE-TIMI 70 Trial Brian Bergmark

4m 22s

Part 3 | Session 6 ACC 22: Results from the POISE-3 Trial Philip J Devereaux

6m 30s

Part 3 | Session 7 ACC 22: ICD Shock Therapies and the Burden of Ventricular Tachycardia Paolo Della Bella

6m 3s

Part 3 | Session 8 ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab Lorenz Räber

3m 31s

Part 3 | Session 9 ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a) Steven E Nissen

4m 48s

Part 3 | Session 10 ACC 22: Results From a sub-study of the POISE-3 Trial Maura Marcucci

2m 55s

Part 3 | Session 11 ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials Michael J Reardon

7m 44s

Part 3 | Session 12 ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR Duk-Woo Park

5m 41s

Part 3 | Session 13 ACC 22: Results From the Chocolate-Touch Study

2m 25s

Part 3 | Session 14 ACC 22: Results from the GIPS-IV Trial Pim van der Harst, Marie-Sophie de Koning

9m 27s

Part 3 | Session 15 ACC 22: FFR vs. IVUS-guided PCI in Intermediate Coronary Artery Stenosis: The FLAVOUR Trial Bon-Kwon Koo

5m 35s

Part 3 | Session 16 ACC 22: Results From the EMPULSE Study – Empagliflozin Proves Beneficial for Patients With HF Mikhail Kosiborod

Average (ratings)

No ratings

Your rating

Overview

Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.

For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA)talks with principal investigators in her regular Late-Breaker Discussion Series.

Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.

More from this programme

Part 1

View from the Thoraxcenter

In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their analysis of the late-breaking trials that will be presented at ACC 2022.

2 sessions
ACC 22 Late-breaking Science Preview	Watch now
ACC.22 Late-breaking Science Wrap-Up	Watch now

Part 2

Late-breaker Discussion Series

Host, Dr Harriette Van Spall interviews the late-breaker presenters of ACC Scientific Sessions 2022.

4 sessions
ACC 2022 Late-breaker Discussion: The SODIUM-HF Trial	Watch now
ACC 2022 Late-breaker Discussion: The SuperWIN Trial	Watch now
ACC 22 Late-breaker Discussion: The PROMPT-HF Trial	Watch now
ACC 22 Late-breaker Discussion: The DIAMOND Trial	Watch now

Part 3

Expert Interviews

19 sessions
ACC 22: Findings from the VALOR-HCM Trial	Watch now
ACC 22: MAVA-LTE Shows Improvement in NYHA Class in Patients Treated with Mavacamten	Watch now
ACC 22: Results From the PACIFIC AF Trial	Watch now
ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease	Watch now
ACC 22: Results from the TRANSLATE-TIMI 70 Trial	Watch now
ACC 22: Results from the POISE-3 Trial	Watch now
ACC 22: ICD Shock Therapies and the Burden of Ventricular Tachycardia	Watch now
ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab	Watch now
ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)	Watch now
ACC 22: Results From a sub-study of the POISE-3 Trial	Watch now
ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials	Watch now
ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR	Watch now
ACC 22: Results From the Chocolate-Touch Study	Watch now
ACC 22: Results from the GIPS-IV Trial	Watch now
ACC 22: FFR vs. IVUS-guided PCI in Intermediate Coronary Artery Stenosis: The FLAVOUR Trial	Watch now
ACC 22: Results From the EMPULSE Study – Empagliflozin Proves Beneficial for Patients With HF	Watch now
ACC 22: Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events	Watch now
ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study	Watch now
2022 AHA/ACC/HFSA Guideline for HF Management: Highlights & Implementation	Watch now

Part 4

Late-breaking Highlights

3 sessions
ACC 22: 3 Trials That Will Change Your Practice with Dr Purvi Parwani	Watch now
ACC 22: 5 Trials That Will Change Your Practice with Interventionalist, Dr Mirvat Alasnag	Watch now
4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos	Watch now

Faculty Biographies

Paul M Ridker

Paul M Ridker

Senior Physician, Brigham and Women's Hospital Eugene Braunwald Professor of Medicine, Harvard Medical School

Dr Paul M Ridker is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital (BWH). A cardiovascular medicine specialist, he is also the Eugene Braunwald Professor of Medicine at Harvard School of Medicine (HMS).

Dr Ridker received his medical degree from HMS. He then completed an internal medicine residency and a cardiology fellowship at BWH. He has authored over 500 peer-reviewed publications, 150 reviews and book chapters, and five textbooks related to cardiovascular medicine. Dr Ridker’s primary research focus has involved inflammatory mediators of heart disease and the molecular and genetic epidemiology of hemostasis and thrombosis, with particular interests in biomarkers for coronary disease, “predictive” medicine, and the underlying causes and prevention of atherosclerotic disease.

View full profile